Upadacitinib Nitroso impurity 1
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Upadacitinib is used to treat moderate to severely active rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis (a type of arthritis in the spine) with objective signs of swelling, moderate to severe ulcerative colitis, moderate to severe Crohn's disease.Upadacitinib Nitroso impurity 1 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Upadacitinib Nitroso impurity 1 CAS NO:NA Chemically represented as (3S,4R)-3-Ethyl-4-(3-nitroso-3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide . Synchemia is the leading manufacturing and exporter of Upadacitinib Nitroso impurity 1. We supply Upadacitinib Nitroso impurity 1 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0142611 |
| CAS No | NA |
| Mol.F. | C14H18Cl2N2O2 |
| Mol.Wt. | 317.21g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142612 |
| CAS No | NA |
| Mol.F. | C18H27N3O2 |
| Mol.Wt. | 317.43 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142613 |
| CAS No | NA |
| Mol.F. | C15H21N3O2 |
| Mol.Wt. | 275.35 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142614 |
| CAS No | NA |
| Mol.F. | C15H20ClN3O2 |
| Mol.Wt. | 309.79 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142615 |
| CAS No | NA |
| Mol.F. | C16H23ClN3O2 |
| Mol.Wt. | 324.83 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142616 |
| CAS No | NA |
| Mol.F. | C18H26BrN3O2 |
| Mol.Wt. | 396.33 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142617 |
| CAS No | NA |
| Mol.F. | C18H26ClN3O2 |
| Mol.Wt. | 351.88 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142618 |
| CAS No | NA |
| Mol.F. | C18H27N3O2 |
| Mol.Wt. | 317.43 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142619 |
| CAS No | NA |
| Mol.F. | C16H23N3O2 |
| Mol.Wt. | 289.38 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142620 |
| CAS No | NA |
| Mol.F. | C17H25N3O2 |
| Mol.Wt. | 303.41 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142621 |
| CAS No | NA |
| Mol.F. | C18H27N3O3 |
| Mol.Wt. | 333.43 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142622 |
| CAS No | NA |
| Mol.F. | C5H7N3O2S |
| Mol.Wt. | 173.2 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142623 |
| CAS No | NA |
| Mol.F. | C11H9ClN6O2S |
| Mol.Wt. | 324.7 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142624 |
| CAS No | NA |
| Mol.F. | C11H9ClN6O2S |
| Mol.Wt. | 324.7 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142625 |
| CAS No | NA |
| Mol.F. | C9H6ClN7O2S |
| Mol.Wt. | 311.7 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0142626 |
| CAS No | NA |
| Mol.F. | C12H15ClN2O3 |
| Mol.Wt. | 270.7 g/mol |
| INV STATUS | CUSTOM SYNTHESIS |